Literature DB >> 18524682

Fiber-modified recombinant adenoviral constructs encoding hepatitis C virus proteins induce potent HCV-specific T cell response.

Duangtawan Thammanichanond1, Sarah Moneer, Patricia Yotnda, Campbell Aitken, Linda Earnest-Silveira, David Jackson, Margaret Hellard, James McCluskey, Joseph Torresi, Mandvi Bharadwaj.   

Abstract

Hepatitis C virus (HCV)-specific cytotoxic T lymphocytes (CTLs) play an important role in HCV clearance. The frequency of HCV-specific T(CD8) in peripheral blood of HCV-infected donors is very low and HCV cannot be cultivated for reinfection of antigen presenting cells, making it difficult to detect T(CD8) of broad HCV specificities from peripheral blood mononuclear cells (PBMCs). We have developed a recombinant adenoviral system that efficiently reactivates and expands HCV-specific CTLs from PBMCs of HCV-infected donors. Replication-incompetent adenoviruses expressing individual HCV proteins (core and NS3) were produced and PBMCs from HCV-infected donors were transduced with these recombinant adeno-HCV constructs to stimulate HCV-specific CTL populations. T cells expanded from adeno-HCV stimulated cultures were potent producers of HCV-specific IFN-gamma and TNF-alpha and efficiently lysed target cells pulsed with HCV peptides. These constructs could stimulate T(CD8) directed towards multiple HCV peptides while preserving the determinant hierarchy. This approach therefore overcomes some of the shortcomings of the selective expansion of CTLs with peptide-based vaccine strategies. These findings provide an effective approach for the expansion of HCV-specific CTLs from PBMCs of HCV-infected patients and have potential for immunotherapeutic/vaccine development.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18524682     DOI: 10.1016/j.clim.2008.04.002

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  8 in total

1.  Identification and retrospective validation of T-cell epitopes in the hepatitis C virus genotype 4 proteome: an accelerated approach toward epitope-driven vaccine development.

Authors:  Karim M Abdel-Hady; Andres H Gutierrez; Frances Terry; Joe Desrosiers; Anne S De Groot; Hassan M E Azzazy
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 2.  New insights on adenovirus as vaccine vectors.

Authors:  Marcio O Lasaro; Hildegund C J Ertl
Journal:  Mol Ther       Date:  2009-06-09       Impact factor: 11.454

3.  Immune response of cytotoxic T lymphocytes and possibility of vaccine development for hepatitis C virus infection.

Authors:  Kazumasa Hiroishi; Junichi Eguchi; Shigeaki Ishii; Ayako Hiraide; Masashi Sakaki; Hiroyoshi Doi; Risa Omori; Michio Imawari
Journal:  J Biomed Biotechnol       Date:  2010-05-20

4.  Prophylactic and Therapeutic Vaccination against Hepatitis C Virus (HCV): Developments and Future Perspectives.

Authors:  Marian E Major
Journal:  Viruses       Date:  2009-08-12       Impact factor: 5.048

5.  The development of Chinese specific human cytomegalovirus polyepitope recombinant vaccine.

Authors:  Ping Zhao; Dao-Xin Ma; Shuang Yu; Fu-Zhong Xue; Wei-Wei Zhu; Na Shao; Jing-Ru Zhang; Chun-Yan Ji
Journal:  Antiviral Res       Date:  2011-12-13       Impact factor: 5.970

6.  Construction and preparation of three recombinant adenoviruses expressing truncated NS3 and core genes of hepatitis C virus for vaccine purposes.

Authors:  Seyed Younes Hosseini; Farzaneh Sabahi; Seyed Mohammad Moazzeni; Mohammad Hossein Modarressi; Mehdi Saberi Firoozi; Mehrdad Ravanshad
Journal:  Hepat Mon       Date:  2012-08-14       Impact factor: 0.660

7.  Enhanced virus-specific CD8+ T cell responses by Listeria monocytogenes-infected dendritic cells in the context of Tim-3 blockade.

Authors:  Cheng J Ma; Jun P Ren; Guang Y Li; Xiao Y Wu; Dirk G Brockstedt; Peter Lauer; Jonathan P Moorman; Zhi Q Yao
Journal:  PLoS One       Date:  2014-01-31       Impact factor: 3.240

8.  A Novel Adeno-Associated Virus-Based Genetic Vaccine Encoding the Hepatitis C Virus NS3/4 Protein Exhibits Immunogenic Properties in Mice Superior to Those of an NS3-Protein-Based Vaccine.

Authors:  Fengqin Zhu; Tian Chen; Yeqiong Zhang; Haixia Sun; Hong Cao; Jianxi Lu; Linshan Zhao; Gang Li
Journal:  PLoS One       Date:  2015-11-10       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.